Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10467154 | 0.87 | KMT2A (0.53) | ATMKMT2APOLBNPC1RAB9A | |
| SCHEMBL28109899 | 0.81 | PARP1 (0.46) | PLA2G10POLBCYP3A4MAPTCYP2C19 | |
| SCHEMBL15428737 | 0.80 | NR3C2 (0.52) | ATMSCN9AKMT2APOLBNPC1 | |
| SCHEMBL15428750 | 0.78 | NR3C2 (0.53) | KMT2ANPC1RAB9AMAPT | |
| SCHEMBL403594 | 0.78 | POLB (0.56) | KMT2APOLBNPC1RAB9AHPGD | |
| SCHEMBL5347073 | 0.77 | SCN9A (0.44) | ATMSCN9ACYP2C9SCN5APOLB | |
| SCHEMBL31010201 | 0.77 | F2 (0.40) | PLA2G10ATMSCN9ACYP2C9SCN5A | |
| SCHEMBL3168308 | 0.77 | POLB (0.53) | CYP2C9KMT2APOLBHPGDCYP3A4 | |
| SCHEMBL9681632 | 0.76 | ATM (0.45) | ATMCYP2C9KMT2APOLBHPGD | |
| SCHEMBL30141511 | 0.74 | MET (0.44) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2010051549-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | PLA2G10 2595/4885ATM 539/4885SCN9A 3424/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | PLA2G10 2595/4885ATM 539/4885SCN9A 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.